This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Understanding the Evolution of Intranasal Vaccines
Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Intranasal Delivery of Vaccines Using Thin Film Freeze-Dried Powders
Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Case Study – Bidose Nasal Spray Pump for Depression
Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
